Druck Icon

Eckert & Ziegler Expects a Balanced Result for 2002 and Income Increase in 2003 despite High Biotechnology Investments

(Ad hoc press release)

Berlin, 12 Feb. 2003 - According to preliminary evaluations, the Eckert & Ziegler AG, a leading European specialist for weakly radioactive medical and industrial products, has been able to achieve an approximately balanced result in 2002, despite high extraordinary expenditures of €3.3 mil. for biotechnological development projects. The sales volume remained persisted at the previous year's level of €32 mil., due to non-recurring effects in the previous year and to the weak exchange rate for the dollar. At the turn of the year 2002-2003, liquid funds had increased to €8.5 mil., or some €300,000 more than on 31 Dec. 2001, despite a dividend payout in May 2002.

Due to the unfavorable dollar exchange rate and dropping sales in the area of cardiovascular radiation sources, the Executive Board does not expect sales increases yet in the current fiscal year. An increase in the result per share to about €0.30 is expected, however. Contributing to this are, for example, a recently concluded bulk order for the delivery of prostate-gland cancer products and a production line, as well as a reduction of expenses in biotechnological developments.

In the latter area of business, animal tests of the pilot product Pankomab™ have now confirmed that in the direct comparison, the antibody, which targets a pancarcinomic antigen, accumulates in tumors better than competing products. The definitive presentation of the data by NEMOD Immuntherapie AG, in which Eckert & Ziegler AG has a share, is expected in approximately mid-March.

The Executive Board of Eckert & Ziegler AG has applied to the German Stock Exchange for admission to the Prime Standard.

The Board of Directors